3,4-二溴-2-硝基噻吩 | 35633-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3,4-二溴-2-硝基噻吩
• 英文名称: dibromo-3,4 nitro-2 thiophene
• 英文别名: 2-nitro-3,4-dibromothiophene；3,4-dibromo-2-nitrothiophene；3,4-Dibrom-2-nitro-thiophen
• CAS: 35633-91-1
• 化学式: C₄HBr₂NO₂S
• 分子量: 286.931
• InChiKey: SFQCSMOCYWODDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3,4-二溴-2-硝基噻吩 在 甲酸 、 铜 作用下， 生成 4-溴-2-硝基噻吩
  参考文献：
  名称：

  Hurtel, Patrice; Decroix, Bernard; Morel, Jean, Journal of Chemical Research, Miniprint, 1983, # 3, p. 725 - 754

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二溴噻吩 在 硫酸 、 硝酸 作用下， 以 氯仿 为溶剂， 反应 24.0h， 以95%的产率得到3,4-二溴-2-硝基噻吩
  参考文献：
  名称：

  通过功能化噻吩前体开发新型噻吩并四氮杂卟啉

  摘要：

  摘要含有中心和轴向取代的硼原子的噻吩并稠合亚卟啉 (TP) 是一类具有有趣的光学和氧化还原特性的化合物。在这里，我们展示了我们使用通过氰化或硝化 3,4-二溴噻吩制备的各种噻吩底物来扩展此类化合物的努力。此外，我们表明一种 TP 衍生物在固态下与 C70 形成 2:1 的复合物。图形概要

  DOI：

  10.1080/17415993.2020.1753190

文献信息

• [EN] INHIBITORS OF JUN N-TERMINAL KINASE<br/>[FR] INHIBITEURS DE L'ENZYME JUN N-TERMINAL KINASE
  申请人：ELAN PHARM INC

  公开号：WO2010091310A1

  公开（公告）日：2010-08-12

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N-末端激酶（JNK）抑制剂（I）的结构，或其盐或溶剂化物，其中环A，Ca，Cb，Z，R5，W和Cy在此处定义。本公开还提供了包括本公开化合物的药物组合物，以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病。
• Kinetics of the reactions of some 5-bromo-2-nitro-3-R-thiophens, 3,4-dibromo-2-nitro-5-R-thiophens, 3-bromo-2-nitro-5-R-thiophens, and 2-bromo-3-nitro-5-R-thiophens with nucleophiles in methanol
  作者：Giovanni Consiglio、Domenico Spinelli、Salo Gronowitz、Anna-Britta Hörnfeldt、Britta Maltesson、Renato Noto

  DOI：10.1039/p29820000625

  日期：——

  The reactivity of some 5-bromo-2-nitro-3-R-thiophens (la–g; R = H, Me, Et, Prn, n-hexyl, Pr1, and But), 3,4-dibromo-2-nitro-5-R-thiophens (IIa and b; R = H and Me), 3-bromo-2-nitro-5-R-thiophens (IIIa and b; R = H and Me), and 2-bromo-3-nitro-5-R-thiophens (IVa and b; R = H and Me) with amines and sodium benzenethiolate has been studied in-methanol at various temperatures. Piperidinodebromination of

  一些5-溴-2-硝基- 3-R-thiophens的反应性（1a-g中; R = H，Me，乙基，丙基Ñ，正己基，镨1和Bu吨），3,4-二溴-2-硝基-5-R-噻吩（IIa和b; R = H和Me），3-溴-2-硝基-5-R-噻吩（IIIa和b; R = H和Me）和2-溴化3-硝基-5-R-噻吩（IVa和b； R = H和Me）与胺和苯硫醇钠在甲醇中的各种温度下进行了研究。还已经在苯，二恶烷和二恶烷水中（60:40和10:90）研究了化合物（Ia和C）的哌啶合溴化。不依赖于烷基的位置（间位或对位 关于离去的溴），已经观察到意外的烷基活化，这代表了烷基的电子释放行为的另一个例外。
• Synthesis in the thienobenzoxazepine series. First synthesis of a diethienoxazepine
  作者：Gilles Marchand、Bernard Decroix、Jean Morel

  DOI：10.1002/jhet.5570210348

  日期：1984.5

  In an investigation of novel tricyclic systems, synthesis of several thieno[2,3-b][1,4]benzoxazepines and thieno[3,2-b][1,5]benzoxazepines were effected by ring closure of appropriately amino aldehyde compounds. A new oxazepine fused with two heterocyclic rings, the dithieno[3,2-b:2,3-f][1,4]oxazepine, is described.

  在新型三环系统的研究中，通过适当氨基醛化合物的闭环作用，合成了几种噻吩并[2,3- b ] [1,4]苯并x氮杂和噻吩并[3,2- b ] [1,5]苯并氮杂s 。描述了一种新的与两个杂环稠合的奥沙西平，即二噻吩并[3,2- b：2,3- f ] [1,4]奥沙西平。
• Heterocyclic-ring condensed benzothiazine compound
  申请人：Eisai Co., Ltd.

  公开号：US06583138B1

  公开（公告）日：2003-06-24

  The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like. Further, the heterocyclic ring condensed benzothiazine compound of the present invention, its pharmacologically acceptable salt or hydrates thereof is represented by the following formula: In the formula, the ring Het represents an unsaturated heterocyclic ring; R1 and R2 are the same as or different from each other, and each represents halogen atom, a lower alkyl group that may be substituted with a halogen atom, a lower alkoxy group that may be substituted with a halogen atom, a lower alkyl lower alkoxy group, cyano group; D represents a lower alkylene group and the like that may have a substituent; Q represents, for example, the formula —NR20R2 (in the formula, R20 and R21 are the same as or different from each other, and each represents hydrogen atom, a lower alkyl group that may be substituted with a halogen atom, an aryl group that may have a substituent, an arylalkyl group that may have a substituent, a heteroaryl group that may have a substituent or a heteroarylalkyl group that may have a substituent, or R20 and R21 may form a 3- to 8-membered ring along with the nitrogen atom to which they are bound); and x represents an integer of from 1 to 2.

  该发明提供了一种新型的杂环环扎缩苯并噻嗪化合物，对于预防或治疗组织胺、白三烯等参与的疾病有效。本发明的杂环环扎缩苯并噻嗪化合物或其药理学上可接受的盐对于预防或治疗组织胺、白三烯等化学介质参与的疾病（例如哮喘、过敏性鼻炎、特应性皮炎、荨麻疹、花粉热、胃肠道过敏、食物过敏等）有效。此外，本发明的杂环环扎缩苯并噻嗪化合物、其药理学上可接受的盐或其水合物由以下公式表示：在该公式中，环Het代表不饱和杂环环；R1和R2相同或不同，每个代表卤素原子、可能被卤素原子取代的较低烷基基团、可能被卤素原子取代的较低烷氧基团、较低烷基较低烷氧基团、氰基；D代表可能有取代基的较低烷基基团等；Q代表，例如，式—NR20R2（在该式中，R20和R21相同或不同，每个代表氢原子、可能被卤素原子取代的较低烷基基团、可能有取代基的芳基团、可能有取代基的芳基烷基团、可能有取代基的杂芳基团或可能有取代基的杂芳基烷基团，或者R20和R21可以与它们结合的氮原子一起形成3-至8-成员环）；x代表1到2的整数。
• Inhibitors of Jun N-terminal kinase
  申请人：Sham Hing L.

  公开号：US08450363B2

  公开（公告）日：2013-05-28

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供具有以下公式结构的c-Jun N末端激酶（JNK）抑制剂：或其盐或溶剂，其中环A、Ca、Cb、Z、R5、W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法，例如，在治疗和预防各种疾病，如阿尔茨海默病方面的应用。